Company Filing History:
Years Active: 2023
Title: Lukas Bunse - Innovator in Cancer Vaccine Development
Introduction
Lukas Bunse is a prominent inventor based in Heidelberg, Germany. He has made significant contributions to the field of cancer research, particularly in the development of innovative vaccines aimed at treating various cancer diseases.
Latest Patents
Lukas Bunse holds a patent for his work on histone anti-cancer vaccines. This invention pertains to novel immunogenic peptide sequences that can be utilized as vaccines in the treatment of cancer diseases, including brain cancers such as glioma. The cancer vaccines are designed based on the K27M mutated variant of human Histone 3. His patent also includes fusion proteins comprising the sequences of the cancer vaccines, nucleic acids encoding such vaccines, and vectors and host cells that incorporate these sequences. Furthermore, the invention involves T cells and T cell receptors that bind to the cancer vaccines, particularly when presented by the human Major Histocompatibility Complex (MHC). The peptide immunogens elicit a HLA-restricted immune response, making them valuable in treating cancer diseases, especially glioma. Additional aspects of the invention include pharmaceutical compositions and diagnostic methods based on the immunogenic capacity of the disclosed peptides.
Career Highlights
Lukas Bunse has worked with notable institutions, including the German Cancer Research Center (Deutsches Krebsforschungszentrum) and the German Cancer Research Center Foundation of Public Law (Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts). His work has been instrumental in advancing cancer treatment methodologies.
Collaborations
Lukas has collaborated with esteemed colleagues such as Michael Platten and Theresa Bunse, contributing to the collective effort in cancer research and vaccine development.
Conclusion
Lukas Bunse's innovative work in the field of cancer vaccines showcases his dedication to improving treatment options for patients suffering from cancer. His contributions are paving the way for future advancements in immunotherapy.